Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper

Currently two intravitreally applied corticosteroids (dexamethasone and fluocinolone) are licensed in Germany for treatment of diabetic macular oedema (DME). The use of DEX implant for DME in daily clinical practice has not been defined in detail. Following a Delphi panel survey, a group of retina e...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Klinische Monatsblatter fur Augenheilkunde Ročník 238; číslo 1; s. 73
Hlavní autori:	Augustin, Albert J, Feltgen, Nicolas, Haritoglou, Christos, Hoerauf, Hans, Maier, Mathias M, Mardin, Christian Yahya, Schargus, Marc
Médium:	Journal Article
Jazyk:	German
Vydavateľské údaje:	Germany 01.01.2021
Predmet:	Angiogenesis Inhibitors - therapeutic use Clinical Decision-Making Consensus Dexamethasone - therapeutic use Diabetes Mellitus Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Drug Implants Germany Glucocorticoids - therapeutic use Humans Intravitreal Injections Macular Edema - drug therapy Macular Edema - etiology Vascular Endothelial Growth Factor A Germany
ISSN:	1439-3999, 1439-3999
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!